Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00298-9/fulltext?dgcid=hubspot_update_feature_updatealerts_lanres&utm_campaign=update-lanres&utm_medium=email&_hsmi=290054570&_hsenc=p2ANqtz-9LtOAw2JWCRMcDq9xuDsDy_JNZbj3LwdZkUOon0fhB0OqxEcCFR0i6WOZK2OU4KWacNk8NyHTaH4y93s5yhgwfzOuzaA&utm_content=289772554&utm_source=hs_email